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Abstract 
Cannabis can induce acute psychotic symptoms in healthy individuals and exacerbate pre-
existing psychotic symptoms in patients with schizophrenia. Inappropriate salience allocation 
is hypothesised to be central to the association between dopamine dysregulation and 
psychotic symptoms. This study examined whether cannabis use is associated with self-
reported salience dysfunction and schizotypal symptoms in a non-clinical population. 910 
University students completed the following questionnaire battery: the cannabis experience 
questionnaire modified version (CEQmv); schizotypal personality questionnaire (SPQ); 
community assessment of psychic experience (CAPE); aberrant salience inventory (ASI). 
Mediation analysis was used to test whether aberrant salience mediated the relationship 
between cannabis use and schizotypal traits. Both frequent cannabis consumption during the 
previous year and ASI score predicted variation across selected positive and disorganised 
SPQ subscales. However, for the SPQ subscales ‘ideas of reference’ and ‘odd beliefs’, 
mediation analysis revealed that with the addition of ASI score as a mediating variable, 
current cannabis use no longer predicted scores on these subscales. Similarly, cannabis use 
frequency predicted higher total SPQ as well as specific Positive and Disorganised subscale 
scores, but ASI score as a mediating variable removed the significant predictive relationship 
between frequent cannabis use and ‘odd beliefs’, ‘ideas of reference’, ‘unusual perceptual 
experiences’, ‘odd speech’, and total SPQ scores. In summary, cannabis use was associated 
with increased psychometric schizotypy and aberrant salience. Using self-report measures in 
a non-clinical population, the cannabis-related increase in selected positive and disorganised 
SPQ subscale scores was shown to be, at least in part, mediated by disturbance in salience 
processing mechanisms.    




Substance misuse is the primary comorbidity in schizophrenia, with cannabis being the most 
commonly misused illicit substance (Adan et al., 2017; Hunt et al., 2018). Cannabis use has 
also been implicated as an independent risk factor in the development of psychotic illness 
(Marconi et al., 2016). Genetic and psychometric risk for psychosis, as well as age and 
lifetime history of cannabis exposure, are significant factors in relation to later risk for 
developing psychosis following cannabis exposure (Stefanis et al., 2004). Cannabis (or Δ9-
tetrahydrocannabinol [THC], the primary psychoactive ingredient of cannabis) can induce 
acute psychotic symptoms in healthy individuals (Bhattacharyya et al., 2009), exacerbate pre-
existing psychotic symptoms in patients with schizophrenia (D’Souza et al., 2005), and might 
increase risk of schizophrenia after long-term use (Marconi et al., 2016).  
Some authors have emphasised the role of mesostriatal dopaminergic activity in assigning 
salience to environmental stimuli, and their potential relevance to the development of 
psychotic symptoms (Kapur, 2003; Winton-Brown et al., 2014). The key role for “aberrant 
salience” in precipitating the emergence of psychotic symptoms has been supported by 
empirical studies showing that expression of psychosis-like symptoms is associated with 
salience misattribution in both patients with schizophrenia (Roiser et al., 2009) and healthy 
controls with increased psychometric risk for psychosis (Stefanis et al., 2013). THC 
administration in healthy individuals also has a significant impact on salience processing, and 
these changes are accompanied by alterations in striatal dopaminergic function (Bossong et 
al., 2009; Wijayendran et al., 2018). 
Aberrant salience has been measured using both performance-based and self-report 
instruments (Cicero et al., 2010; Roiser et al., 2009). The aberrant salience inventory (ASI) is 
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a questionnaire designed to measure salience disturbance and has been validated across 
diverse population samples (Cicero et al., 2010; Raballo et al., 2017). ASI scores are 
associated with increased psychometric risk for psychosis (Cicero et al., 2010, 2013). 
Lifetime exposure to psychosocial stressors implicated in schizophrenia has been associated 
with increased ASI scores (Gaweda et al., 2019; McCutcheon et al., 2019). Additionally, 
frequent cannabis use was associated with higher ASI scores in a university student sample 
(Bernardini et al., 2018).  
Schizophrenia is conceptualised as a heterogeneous disorder, with clinically defined 
psychotic illness existing on a continuum with normal behaviour (Van Os et al., 2009). This 
dimensional view proposes that “schizotypal” traits map onto a continuum of psychosis 
proneness from subclinical psychotic ideation through to florid psychotic symptoms such as 
delusions and hallucinations (Linscott and van Os, 2013; Raballo et al., 2017; Gaweda et al., 
2019; Grant et al., 2018). As individuals with heightened levels of schizotypy may be at 
greater risk for later development of a schizophrenia-spectrum disorder, studies employing 
schizotypal participants provide an opportunity to examine factors that might precede the 
onset of illness. Schizotypal traits have also been shown to be higher in cannabis users (see 
Szoke et al., 2014 for review of studies), hence schizotypal characteristics may be 
conceptualised as a consequence of early and heavy cannabis use, or a predictor of the 
psychotogenic effects of cannabis exposure (Bailey and Swallow, 2004). Alternatively, it has 
been proposed that other variables, which may include putative psychological mechanisms 
underlying psychotic experiences, may mediate the influence the relationship between 
cannabis use and the development of schizotypal traits (Dumas et al., 2002).  
A better understanding of the mechanistic basis underlying the cannabis-psychosis 
association is dependent upon further research focusing on changes in salience processing as 
a principal outcome related to long-term cannabis use (Wijayendran et al., 2018). It is 
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hypothesised that increased aberrant salience, assessed using the ASI, mediates the 
association between cannabis use and psychometric liability for psychosis, as measured by 
schizotypy scales and self-reported experience of psychotic symptoms and daily life stress 
experiences. In the current study we investigated whether cannabis use parameters were 
associated with self-reported abnormality in salience processing and whether this is 
associated with higher schizotypy.   
 
2. Methods 
All participants were volunteers who provided informed consent according to procedures 
approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals.  
    2.1 Participants 
Participants were undergraduate and postgraduate students of University College Cork (UCC) 
and Cork Institute of Technology (CIT). The sample consisted of 910 students (from a total 
eligible sample of 16,200, corresponding to a response rate of 5.6%), with no declared history 
of neurological disorder or any formal psychiatric diagnosis during their life. Participants 
were recruited through distribution, via email, of a link to the questionnaire battery, hosted on 
surveymonkey.com [Portland, Oregon, USA]. No incentive to participate in this study was 
offered to students. 
    2.2 Measures 
The following questionnaires were employed in this study: ASI (Cicero et al., 2010), 
Schizotypal Personality Questionnaire (SPQ; Raine, 1991), Community Assessment of 
Psychic Experiences (CAPE; Hanssen et al., 2003) and the Cannabis Experience 
Questionnaire modified version (CEQmv; Di Forti et al., 2009). The latter questionnaire also 
 6 
measured a number of socio-demographic characteristics including age, sex, nationality, and 
education level.  
The ASI is a 29-item self‐report measure of aberrant salience. Each item requires a ‘yes’ or 
‘no’ response in relation to lifetime experiences. The ASI yields a total score calculated as 
number of positive responses and has the following five subscales: Increased significance; 
Senses sharpening; Impending understanding, Heightened emotionality; Heightened 
cognition. The ASI has been shown to have good reliability and validity for measuring 
aberrant salience in patients with a psychosis history as well as in non-clinical samples 
(Cicero et al., 2010). 
The SPQ is a 72‐item index of schizotypy, based on DSM-IIIR criteria for schizotypal 
personality disorder, that can be measured in the general population. The SPQ comprises nine 
subscales that form three dimensions: (a) Cognitive‐perceptual/Positive (including the four 
subscales ‘ideas of reference’, ‘odd beliefs’, ‘unusual perceptual experiences’, ‘paranoid 
ideation’); (b) Interpersonal (including the four subscales ‘excessive social anxiety’, ‘no close 
friends’, ‘constricted affect’, ‘paranoid ideation’); and (c) Disorganised (including the two 
subscales ‘odd or eccentric’, ‘odd speech’) (Raine et al., 1994). The SPQ uses a dichotomous 
response format. A total SPQ score was based on the sum of all nine subscale scores.  
The CAPE is a 42-item self-report scale developed to assess the frequency of clinical 
symptoms and severity of symptom-related distress in the general population (Stefanis et al., 
2002). It evaluates three symptom clusters observed in severe cases of psychiatric illness: 
positive, negative, and depressive. The CAPE uses a 4-point Likert scale (0-3) to indicate 
frequency of symptoms (“Never”, “Sometimes”, “Often”, and “Nearly always”), and a 4-
point scale to demonstrate degree of distress experienced as a result of symptoms if present 
(“Not distressed”, “A bit distressed”, “Quite distressed”, “Very distressed”).  
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The CEQmv was administered to collect data on consumption of cannabis (and of other drugs 
of abuse). This questionnaire explores cannabis consumption in detail, including: age at first 
use, lifetime cannabis consumption, current cannabis consumption (defined as frequent use of 
cannabis consumption during the previous 12 months), frequency of use, consumption of 
other drugs. Previous studies have compared participants that never used cannabis with those 
who did use cannabis (“ever vs. never”), as well as participants that used cannabis at the time 
of the study relative to participants that did not use cannabis at that time (“current” vs. 
“other” comparison) (see Szoke et al., 2014, for review). Definitions of “current” use vary 
across studies, but several have defined it as frequent intake during the preceding year (e.g. 
van Gastel et al., 2012). The present study categorised cannabis use as (a) lifetime use (“ever 
vs. never”), (b) current use (frequent use during previous year, yes/no), or (c) cannabis use 
frequency (5-level ordinal variable; every day, more than once a week, a few times each 
month, a few times each year, only once or twice (ever)).      
 
    2.3 Data Analysis 
All univariate statistical analyses were performed using SPSS Version 24 (IBM Corporation, 
Armonk, NY) with an alpha level set at p ≤ 0.05 (two-tailed) for all outcomes. Kolmogorov-
Smirnov analysis conducted on ASI, SPQ, and CAPE values revealed that these data were not 
normally distributed. Therefore, the Mann-Whitney U test or Kruskal Wallis analysis of 
variance were conducted to compare variation across measures between two groups (e.g. 
gender) or greater than two groups (e.g. cannabis use frequency), respectively. The Cliff’s 
delta (|d|) statistic was used to study effect size. Pearson’s Chi-square test was used to test 
relationships between categorical variables. Correlation analysis was carried out using 
Spearman’s rho where the Holm-Bonferroni adjustment for multiple comparisons was used. 
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Based on univariate analyses that examined the relationships between cannabis use and SPQ 
and CAPE scores (Table 3), mediation analysis was used to test the hypothesis that aberrant 
salience (i.e. ASI score) mediates the association between cannabis use and SPQ scores, 
controlling for gender.  To assess the mediating role of ASI, two regression models were 
conducted: the first baseline model (model 1) containing SPQ total or SPQ sub-scale as the 
outcome, current cannabis use or cannabis use frequency as the main predictor, and gender as 
a control variable; the second mediation model (model 2) repeated this process with ASI as a 
potential mediator variable.  To assess mediation, we focused on the reduction in co-efficient 
of cannabis use from the baseline model (assuming a significant prediction at the baseline 
model level) to the mediation model, and whether ASI is a significant predictor of SPQ score. 
These models were also compared with Likelihood ratio tests, and both Akaike information 
criterion (AIC) and Bayesian information criterion (BIC) were presented as goodness of fit 
measures. As the outcome variable of SPQ total and its subscales were both non-normally 
distributed and on an ordinal scale, linear regression was deemed inappropriate. Instead, a 
Poisson distribution was used which more accurately approximated the SPQ distributions. 
Additionally, as there were “0” counts in the data across all outcomes (participants scoring 
“0”) a zero-inflated Poisson (ZIP) model was adopted for our analyses, with the data for both 
model components presented in the summary tables. These components are two individual 
regressions that form a single statistical: A Poisson component aiming to explain variance in 
SPQ scores 1 and above (i.e., without “0” values) and a Zero component which contrasts 
those that score exactly “0” and those that scores 1 or above (i.e., a binary logistic 
regression). Therefore, model performance statistics (e.g., AIC, BIC, etc.) refer to both these 
components simultaneously. The analysis focuses primarily on the first Poisson component 
for interpretability due to the large number of analyses. Two exceptions are the zero 
components for SPQ total for current cannabis use and cannabis use frequency (Table 6). 
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Only six 0 scores for SPQ total were observed meaning the “0” was severely smaller than the 
comparison group, leading to inflated standard errors. This is especially prominent for 
cannabis use frequency, as some cross tabulations did not include an observation. The 
subscales however had higher levels of 0 values ranging from 82 for ‘excessive social 
anxiety’ up to 352 for ‘odd beliefs’; meaning this approach was more appropriate.  However, 
these Zero components are reported for transparency but not considered for interpretation.  
Confidence intervals were bootstrapped (10000 replications) and extracted using the BCa 
method.  As traditional R2 is primarily appropriate for simple linear regression, pseudo-R2 is 
instead used here. This was calculated as the squared correlation between actual and 
predicted model values. This value was also adjusted for multiple predictors. These analyses 
were conducted in R Studio (RStudio Team, 2015, version 3.6.0) using the “pscl” package. 
 
3. Results 
Table 1 and Supplementary Table 1 present the socio-demographic and cannabis use 
characteristics of the study sample. No sex differences were observed for lifetime cannabis 
use (χ2 = 1.25, P = 0.29), but male respondents were more likely to be current cannabis users 
at the time of the study (χ2 = 8.15, P = 0.003) and were more frequent cannabis users (χ2 = 
14.75, P = 0.005). Family history of mental illness was associated with increased likelihood 
of lifetime cannabis use (χ2 = 17.03, P < 0.001) and current cannabis use (χ2 = 4.70, P = 
0.02). Neither family history of neurological illness nor highest education level achieved 
were associated with any cannabis use parameter (all P > 0.05).   
Summary scores for the ASI, SPQ, and CAPE scales are presented in Supplementary Table 2. 
Females displayed higher values for the following SPQ subscales: ‘odd beliefs’ (U = 85207, z 
= 3.93, P < 0.001, |d| = 0.13), ‘excessive social anxiety’ (U = 80067, z = 5.03, P < 0.001, |d| = 
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0.15). Males showed higher scores for the ‘constricted affect’ subscale (U = 88076, z = 2.97, 
P = 0.003, |d| = 0.12). No statistically significant effects of sex were observed for ASI and 
CAPE scores. Respondents reporting a family history of mental illness demonstrated 
significantly higher total ASI (U = 73156, z = 4.03, P < 0.001, |d| = 0.17) scores. While 
family history of mental illness had no effect on CAPE frequency or distress scores, family 
history was associated with increased scores across the following sub-scales scores: ‘unusual 
perceptual experiences’ (U = 74113, z = 3.94, P < 0.001, |d| = 0.16), ‘excessive social 
anxiety’ (U = 74591, z = 3.76, P < 0.001, |d| = 0.15), ‘odd or eccentric’ (U = 73559, z = 4.10, 
P <0.001, |d| = 0.16), and ‘paranoid ideation’ (U = 73637, z = 4.04, P < 0.001, |d| = 0.16). For 
both sex and family history variables, the effect sizes for all outcome variables was either 
negligible (|d| ˂ 0.17) or small (0.147 ≤ |d| ˂ 0.33).       
Results of correlational analysis across the ASI, SPQ, and CAPE instruments are presented in 
Table 2. Total ASI score demonstrated significant positive correlations with all SPQ scores 
(total, dimension and subscales); magnitude of correlation coefficients ranged from 0.20-
0.68. No significant correlation was observed between ASI and any CAPE measure. 
Table 3 presents a summary and comparison of ASI (total and subscale), SPQ (total, subscale 
and dimension) and CAPE scores between current cannabis users and their controls. Lifetime 
cannabis use, was not associated with any statistically significant variation in ASI, SPQ or 
CAPE scores (all P > 0.05; Supplementary Table 3). Current cannabis use was associated 
with significantly increased ASI total and all subscale scores (Table 3). Additionally, current 
cannabis users showed increased scores across the Positive (U = 43555, z = -2.95, P = 0.002) 
and Disorganised (U = 40603, z = 4.13, P < 0.001) SPQ dimensions, as well as the SPQ 
subscales ‘ideas of reference’ (U = 43364, z = 3.05, P = 0.002) and ‘odd or eccentric’ (U = 
40016, z = 4.44, P < 0.001). Analysis based on cannabis use frequency revealed that frequent 
consumption was associated with higher scores across the Disorganised SPQ dimension (χ2 = 
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23.52, P < 0.001), as well as the following subscales: ‘odd or eccentric’ (χ2 = 26.90, P < 
0.001); ‘unusual perceptual experiences’ (χ2=12.66, P=0.01); ‘odd speech’ (χ2 = 12.51, P = 
0.01). Higher consumption frequency was also associated with higher ASI scores (χ2 = 
10.72, P = 0.03).    
Age at first use of cannabis was negatively correlated with scores on the SPQ Positive 
dimension (rs = -0.14, P = 0.002), but no other ASI, SPQ or CAPE measure. When asked to 
quantify level of cannabis consumption up to the age of sixteen, no significant differences 
were observed across ASI, SPQ and CAPE scores between participants who consumed less 
than one cannabis joint per day relative to participants who used between one and four joints 
per day (all P > 0.05). No significant relationships were observed between frequency of 
cannabis use up to the age of sixteen and any ASI, SPQ and CAPE measure (all P > 0.05). 
For the mediation analysis the Poisson components were compared between baseline and 
mediation models. For analyses with current cannabis use, “yes” was treated as the reference 
category, with a negative regression coefficient in the Poisson component representing those 
who do not use cannabis have a lower SPQ score and vice versa for a positive coefficient. 
However, a positive coefficient for the zero component predicts that those not currently using 
cannabis are more likely to score “0” relative to scoring 1 or above. Inspection of the Poisson 
components showed that not currently using cannabis was a significant predictor of lower 
SPQ total score (log(odds) = -0.134 [-0.221, -0.046.], P < 0.001; Supplementary Table 4), 
‘odd or eccentric’ (log(odds) = -0.145 [-0.270, -0.015], P = 0.014; Supplementary Table 5) , 
‘ideas of reference’ (log(odds) = -0.150 [-0.270, -0.021], P = 0.004; Table 4), and marginally, 
‘odd beliefs’ (log(odds) = -0.189 [-0.407, 0.046], P = 0.05; Table 5) and ‘odd speech’ 
(log(odds) = -0.083 [-0.189, 0.025], P = 0.07; Supplementary Table 6) subscale scores, in the 
baseline models. Therefore, only the marginally and statistically significant models (SPQ 
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total, ‘odd or eccentric’, ‘ideas of reference’, ‘odd beliefs’, and ‘odd speech’) were carried 
forward for mediation analysis. 
 In these mediation models, ASI total score was found to significantly predict SPQ total score 
(log(odds) = 0.04 [0.038, 0.047], P < 0.001), but cannabis remained a significant independent 
predictor (log(odds) = -0.055 [-0.129, 0.02], P = 0.001), despite showing a 59% reduction in 
its effect following the inclusion of ASI. Similarly, ASI independently predicted ‘odd or 
eccentric’ (log(odds) = 0.029 [0.022, 0.037], P < 0.001), with cannabis continuing to be a 
significant predictor (log(odds) = -0.119 [-0.238, 0.007], P = 0.04), with a 17.9% reduction in 
log(odds). ASI total score was also found to significantly predict ‘ideas of reference’ 
(log(odds) = 0.046 [0.039, 0.052], P < 0.001), but current cannabis was reduced to a marginal 
predictor on this subscale (log(odds) = -0.100 [-0.211, 0.017], P = 0.056; Table 4), 
demonstrating a 33% reduction in its effect. For the SPQ subscale analyses, where current 
cannabis use was a marginal predictor, ASI was a significant predictor in ‘odd speech’ 
(log(odds) = 0.035 [0.029, 0.040], P < 0.001) with current cannabis use becoming non-
significant predictor (log(odds) = -0.037 [-0.136, 0.062], P = 0.44). For ‘odd beliefs’, ASI 
was also a significant predictor (log(odds) = 0.049 [0.039, 0.060], P < 0.001), with cannabis 
use again becoming non-significant (log(odds) = -0.131 [-0.332, 0.085], P = 0.177; Table 5). 
In all cases the mediation models were a better fit to the data than the baseline models, 
evidenced through significant Likelihood ratio tests (all P < 0.001) and lower AIC and BIC 
indices; suggesting the addition of ASI improved the model.  
This process was repeated for current cannabis use frequency which was treated as a 
categorical variable, as the levels of frequency were not equally spaced (e.g., “a few times 
each year”, “a few times each month”, “more than once a week”, etc.). For this analysis, the 
first category of “only once or twice” was used as the reference category with all coefficients 
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representing the change in SPQ when moving from this reference category to another 
category (e.g., “only once or twice” vs. “a few times each month”). Therefore, a positive 
coefficient represents an increase in SPQ score between categories. Each cannabis frequency 
level was a significant predictor of SPQ total score over “only once or twice” (Table 6, all P 
< 0.001) in the baseline model. For the other two subscales that were significant using current 
cannabis use, ‘ideas of reference’ saw an increase in score only for “a few times each month” 
(log(odds) = 0.177 [-0.045, 0.393], P = 0.033; Supplementary Table 7), while ‘odd or 
eccentric’ was significant at “every day” use only (log(odds) = 0.262 [0.004, 0.511], P = 
0.036; Supplementary Table 8). For the subscales that were previously marginally significant, 
‘odd beliefs’ reported an increase in score at “more than once a week” (log(odds) = 0.498 
[0.108, 0.86], P = 0.002; Supplementary Table 9), while ‘odd speech’ showed an increase at 
“a few times each year” (log(odds) = 0.141 [-0.026, 0.312], P = 0.042) and “a few times each 
month” (log(odds) = 0.161 [-0.033, 0.353], P = 0.031; Supplementary Table 10). One major 
difference between these approaches was that significant increases in scores were found for 
‘no close friends’ at “every day” cannabis use (log(odds) = 0.223 [-0.087, 0.477], P = 0.039; 
Supplementary Table 11), and ‘unusual perceptual experiences’ at ‘more than once a week’ 
(log(odds) = 0.355 [0.091, 0.616], P = 0.001; Supplementary Table 12), which were not 
significant in the currently use cannabis models. The remaining scales saw no significant 
differences in the baseline Poisson components. 
In the mediation model, ASI total score was found to significantly predict SPQ total score 
and all nine subscales (P < 0.001), but cannabis use remained a significant predictor of SPQ 
total scores for all frequency categories (all P < 0.05) with exception of ‘> once a week’ 
(log(odds)= -0.017 [-0.153, 0.11], P = 0.608; Table 6). For ‘odd or eccentric’, the significant 
difference at “every day” remained, with a 4.2% reduction. For ‘ideas of reference’ the 
significant prediction of “a few times each month” was no longer significant (log(odds) = 
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0.081[-0.107, 0.26], P = 0.333). ‘Odd beliefs’ saw both significant predictions return as non-
significant (P > 0.05, reduction: 37.2% - 49.6%) while ‘odd speech’ similarly returned no 
significant cannabis predictors (P > 0.05, reduction: 34.8% - 38.5%). ‘No close friends’ saw 
the prediction at “every day” reduced to marginal (log(odds) = 0.192 [-0.122, 0.447], P = 
0.077). For ‘unusual perceptual experiences’, cannabis use (‘more than once a week’) no 
longer predicted scores (log(odds) = 0.164 [-0.041, 0.375], P = 0.127), showing a reduction 
of 19%. As the remaining subscales saw no prediction from any cannabis frequency 
mediation are not reported here. Again, all mediation models were a better fit to the data than 
the baseline models.  
 
4. Discussion 
In the present study, frequent cannabis users reported higher scores across Positive and 
Disorganised schizotypal domains and aberrant salience measures than light users, who in 
turn reported more than those who had minimal cannabis exposure. This apparent ‘dose–
response’ relationship mirrors the relationship between cannabis use and psychotic disorders 
in clinical populations (Henquet et al., 2008), supporting further the association between 
cannabis use and psychosis.  
Current cannabis use (frequent use during the preceding year) was associated with higher 
scores across the Positive and Disorganised SPQ dimensions, and related subscales (i.e. 
‘ideas of reference’, ‘odd or eccentric’). Previous studies have found that cannabis use is 
associated with higher rates of Positive and Disorganised, but not Interpersonal (negative), 
schizotypy traits (Bailey & Swallow, 2004; Schiffman et al., 2005; Earleywine, 2006; Cohen 
et al., 2011; Eren et al., 2017). The present results are consistent with previous reports that 
regular cannabis users on average display more cognitive and perceptual distortions, as well 
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as disorganization, but not interpersonal deficits. In agreement with our hypothesis, while 
current cannabis use and aberrant salience independently predicted variation in selected 
Disorganised (‘odd or eccentric’, ‘odd speech’) or Positive dimensions (‘ideas of reference’, 
‘odd beliefs’), the cannabis-schizotypy association for the ‘ideas of reference’, ‘odd beliefs’, 
and ‘odd speech’ (where the initial cannabis association was marginal), was explained by the 
effect of the drug on aberrant salience processing. A similar profile was observed for self-
reported frequent cannabis use.   Core symptoms of schizophrenia and related disorders, as 
well as psychosis proneness, have been proposed to reflect a disturbance in salience-based 
information processing (Kapur, 2003; Howes & Kapur, 2009). It has been suggested that 
misattribution of salience to irrelevant stimuli might represent one such marker of 
vulnerability to progression to psychosis among high cannabis users (Bernardini et al., 2018). 
Others have suggested that misattribution of significance to otherwise neutral stimuli may 
trigger the phenotypic expression of Positive schizotypal traits (Raballo et al., 2019). The 
present results demonstrate that aberrant salience principally accounts for the effects of 
frequent cannabis use on Positive schizotypal traits, as indexed by scores on the ‘ideas of 
reference’ and ‘odd beliefs’ SPQ sub-scales, while exerting a reduced or non-existent 
mediating influence on cannabis-affected Disorganised sub-scales, as well as global SPQ 
score.   
Current cannabis users showed higher total ASI scores, but lifetime cannabis use was not 
associated with any increase in ASI scores. These results contrast with those of Bernardini et 
al. (2018), where both lifetime and current cannabis users demonstrated higher ASI scores 
relative to non-users. In agreement with studies using ASI or performance-based measures 
such as SAT (Bloomfield et al., 2016; Bernardini et al., 2018), higher cannabis use frequency 
was associated with higher levels of aberrant salience.  
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No effect of either lifetime (i.e. ‘ever vs. never’) or current cannabis use was observed on 
positive, negative or depressive frequency or distress dimensions of the CAPE, a measure of 
recent psychotic-like experiences; these findings contrast with those reported previously for 
CAPE (Schubart et al., 2011; Skinner et al., 2011; Bernardini et al., 2018). This may in part 
be explained by the observation that cannabis effects on SPQ score in the present analyses 
particularly reflects highly significant effects on Disorganised dimension sub-scales. While 
the CAPE has two dimensions for reporting psychotic experiences (positive, negative), it 
does not contain a Disorganisation factor.   Additionally, it should be noted that a non-linear 
relationship between regular cannabis use and CAPE scores has been reported previously, 
with the presence of positive and negative symptoms similarly observed in very regular 
cannabis users and non-cannabis users relative to a group of moderate cannabis users (Brañas 
et al., 2016).  
Research that has investigated the direction of the association between cannabis use and 
development of psychosis has consistently shown that cannabis use precedes the emergence 
of psychotic symptoms (Henquet et al., 2005; Stefanis et al., 2013). Similarly, Hjorthoj et al. 
(2018) demonstrated that conversion from schizotypal disorder to schizophrenia was 
significantly higher among those with cannabis use disorder. The current study design 
precludes conclusions about whether schizotypal traits predispose individuals to use cannabis 
(Wijayendran et al., 2018), or whether cannabis use is associated with an increase in 
schizotypal traits, or indeed whether chronic cannabis use may increase phenotypic 
expression of schizotypal traits in individuals harbouring the latent schizotypy construct 
(Lenzenweger, 2018).  Future research could address this issue by following participants 
longitudinally to establish the temporal precedence of cannabis exposure and aberrant 
salience before the development of psychotic-like experiences. Additionally, such studies 
might also incorporate complementary testing on laboratory-based cognitive measures such 
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as the salience attribution test (SAT) (Roiser et al., 2009), although achieving large sample 
sizes necessary to probe such complex relationships can prove challenging in these 
circumstances.      
In conclusion, we report that aberrant salience is an important mediating variable underlying 
the relationship between current cannabis use and the increase in psychometrically-defined 
positive schizotypy. Further research is required to investigate not only the biological 
substrates underlying the relationship between cannabis use and the development of 
schizophrenia-spectrum symptoms, but also the impact of psychological and psychosocial 
factors modulating the strength of this relationship.  This will ultimately inform the 
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Table 1     Characteristics of the sample population (n=910) 
Characteristic            n % 
 
Sex   
    Female 515 (56.6%) 
    Male 386 (42.4%) 
    Not specified 9 (1.0%) 
Nationality   
    Irish/British 787 (86.5%) 
    Other European 71 (7.8%) 
    North American 14 (1.5%) 
    Asian 13 (1.4%) 
    Other/Not specified 25 (2.8%) 
Highest level of education   
    Secondary level 355 (39.0%) 
    Post-secondary level 122 (13.4%) 
    Primary degree 328 (36.0%) 
    Masters degree 70 (7.7%) 
    Doctoral degree 3 (0.3%) 
    Other/Not specified 32 (3.5%) 
Family history of mental illness   
    Yes 290 (31.9%) 
    No 608 (66.8%) 
    Not specified 12 (1.3%) 
Lifetime cannabis use   
    Yes 469 (51.5%) 
    No 365 (40.1%) 
    Not specified 76 (8.4%) 
Current cannabis use   
    Yes 181 (19.9%) 
    No 563 (61.9%) 
    Not specified 166 (18.2%) 
Age at first cannabis use   
    Mean age (SD) 17.6 (2.7%) 
    Range 7-28  
Frequency of cannabis use   
    Every day 34 (3.7%) 
    Greater than once a week 60 (6.6%) 
    A few times each month  96 (10.5%) 
    A few times each year 123 (13.5%) 
    Only once or twice 163 (17.9%) 
    Not specified 434 (47.7%) 
   
Figures presented are number (%) unless stated otherwise. 
Table 2     Correlations between ASI and both SPQ and CAPE Scores 
Scale  Parameter rs P-value a 
SPQ Total  0.60 < 0.001 
 Ideas of reference 0.55 < 0.001 
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a α value adjusted for multiple comparisons 
 
Table 3   Comparison of ASI, SPQ, and CAPE scores between current cannabis users and 
nonusers 
 Excessive social anxiety 0.27 < 0.001 
 Odd beliefs 0.47 < 0.001 
 Unusual perceptual experiences 0.63 < 0.001 
 Odd or eccentric 0.46 < 0.001 
 No close friends 0.20 < 0.001 
 Odd speech 0.49 < 0.001 
 Constricted affect 0.31 < 0.001 
 Paranoid ideation 0.50 < 0.001 
 Cognitive Perceptual 0.68 < 0.001 
 Interpersonal 0.38 < 0.001 









 Positive dimension 0.03  0.43 
 Positive dimension distress -0.04  0.20 
 Negative dimension -0.04  0.21 
 Negative dimension distress -0.05  0.18 
 Depressive dimension -0.03  0.35 
 Depressive dimension distress -0.04  0.21 




     Current 
cannabis 







95% CI for 
Cliff’s |d|   
(Upper, 
Lower) 
  Mean SD Mean SD    






















1.15 1.32 1.38 1.39    0.032 0.10 (0.008, 
0.192) 
SPQ Total 23.29 14.24 26.27 13.15    0.004 0.14 (0.050, 
0.231) 

















 Excessive social 
anxiety 
3.96 2.67 4.02 2.74    0.78 0.01 (-0.083, 
0.110) 
 Odd beliefs 1.12 1.45 1.26 1.57    0.397 0.04 (-0.053, 
0.131) 
 Unusual perceptual 
experiences 
2.04 1.95 2.43 2.00    0.01 0.12 (0.029, 
0.215) 




 No close friends 3.08 2.58 2.96 2.40    0.76 -0.02 (-0.110, 
0.079) 
 Odd speech 3.29 2.61 3.90 2.53    0.004 0.14 (0.050, 
0.234) 
 Constricted affect 2.33 1.99 2.57 2.00    0.106 0.08 (-0.015, 
0.172) 








 Interpersonal 12.11 7.84 12.54 7.51    0.402 0.04 (-0.053, 
0.135) 




CAPE Total 1.62 0.02 1.66 0.03    0.150 0.09 (-0.190, 
0.201) 
 Positive dimension 1.23 0.30 1.25 0.34    0.391 0.05 (-0.051, 
0.143) 
 Positive dimension 
distress 
2.23 1.58 2.12 1.31    0.490 -0.03 (-0.130, 
0.062) 
 Negative dimension 1.94 0.51 1.94 0.55    0.085 0.00 (-0.096, 
0.100) 
 Negative dimension 
distress 

















a α value adjusted for multiple comparisons; CI, confidence interval; SD, standard deviation 
Table 4   Mediation analysis results predicting SPQ ‘ideas of reference’ subscale scores based on 
current cannabis use 
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Note: Model 1: AIC=3259, BIC=3286.6, % change Poisson=33.3%, Model 2:  AIC=2944.5, BIC=2981.3, % 
change Zero=37.1%, LR test, X2(2) =318.53,  P < 0). CI, confidence interval. GVIF, generalized variance 
inflation factor. OR, odds ratio. SE, standard error. 
           
 
Table 5   Mediation analysis results predicting SPQ ‘odd beliefs’ subscale scores based on 
current cannabis use 
 
    Model Variable Log(odds
) 
95% CI SE OR z P GVI
F 
R2pseudo 
Model 1  
Baseline 
 Odd 



































































































































































































































Note: Model 1: AIC=2174.7, BIC=2202.3, % change Poisson=30.7%, Model 2:  AIC=1957.4, BIC=1994.2, 
reduction Zero=1566.7%, LR test, X2(2) =221.26,  P < 0). CI, confidence interval. GVIF, generalized variance 
inflation factor. OR, odds ratio. SE, standard error. 
           
 
Table 6    Mediation analysis results predicting total SPQ total score based on cannabis 
use frequency 
 
Model  Variable Log(odds) 95% CI SE OR z 
Model 1 SPQ - 
Poisson 
intercept 3.053 [2.923, 3.175] 0.022 21.179 141.85 
Baseline Cannabis: a few times each year 0.171 [0.04, 0.308] 0.025 1.186 6.88 
 Cannabis: a few times each month 0.174 [0.019, 0.33] 0.027 1.19 6.39 
 Cannabis: More than once a week 0.149 [-0.008, 0.308] 0.032 1.161 4.69 
  Cannabis: Every day  0.208 [-0.009, 0.435] 0.038 1.231 5.42 
  Gender 0.01 [-0.094, 0.117] 0.019 1.01 0.53 
Model 2 SPQ - 
Poisson 
intercept 2.643 [2.528, 2.763] 0.025 14.055 105.11 
Mediation Cannabis: a few times each year 0.077 [-0.039, 0.184] 0.025 1.08 3.07 
 Cannabis: a few times month 0.074 [-0.049, 0.194] 0.027 1.077 2.7 
 Cannabis: > than once a week -0.017 [-0.153, 0.11] 0.032 0.983 -0.51 
  Cannabis: Every day  0.078 [-0.1, 0.229] 0.038 1.081 2.03 
  Gender 0.027 [-0.058, 0.114] 0.019 1.027 1.39 
  ASI 0.042 [0.037, 0.047] 0.001 1.043 34.96 
Note: Model 1: AIC=5841.9, BIC=5891.6, Model 2:  AIC=4646.6, BIC=4704.7, LR test, X2(2) =1199.3, P < 0). CI, 
confidence interval. GVIF, generalized variance inflation factor. OR, odds ratio. SE, standard error. 
 
 
     
 
 
 
